NCCN updates bladder cancer guidelines to include ImmunityBio's ANKTIVA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
March 17, 2026 7:30 AM EDTRecommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc.... More
